CLINICAL TRIAL: COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 假说是，硼替佐米和达卡巴肼的联合治疗将提高黑色素瘤和软组织肉瘤的治疗效果。 这些试验的具体目的是：(1)确定达卡巴肼和硼替佐米联合用药的推荐剂量；(2)确定联合用药的最大耐受量；(3)从有效率(S)、有效时间、进展时间和治疗时间(衡量抗肿瘤活性和治疗耐受性)的角度观察抗肿瘤活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypotheses is that combined treatment with bortezomib and dacarbazine will result in enhanced therapeutic efficacy in melanoma and soft tissue sarcoma. The specific Aims are to : (1) Determine the recommended doses for the combination dacarbazine and bortezomib administered weekly; (2) Determine the maximum tolerated dose combination; and (3) Observe anti-tumor activity in terms of response rate(s), duration of response, time to progression, and time on treatment (a measure of both antitumor activity and treatment tolerance).